Economy
MEDEZE Group Named 2026 Company of the Year by Frost & Sullivan
Thai-based MEDEZE Group has secured the 'Company of the Year' award in Southeast Asian stem cell banking and regenerative medicine for the tenth consecutive year.
According to a report by Thai Post, MEDEZE Group has been honored as the 2026 Company of the Year in the Southeast Asian stem cell banking and regenerative medicine sector by the research firm Frost & Sullivan. This recognition marks a decade of consecutive awards for the company, spanning from 2017 to 2026.
Frost & Sullivan highlighted the company’s regional leadership, noting its commitment to innovation, business operational capacity, and the development of comprehensive regenerative medicine platforms. MEDEZE Group has stated its intention to evolve its business model from a 'Biobank' focus toward 'Biopharma' operations, while simultaneously expanding its network across the region. Furthermore, the company has been selected as a private sector participant in Thailand’s Advanced Therapy Medicinal Products (ATMP) Sandbox program.
For residents and those interested in the local healthcare landscape, this milestone underscores the growth of Thailand’s biotechnology sector and its increasing integration into regional medical markets. While the award reflects the company's past performance and current industry standing, the long-term impact of its transition into the biopharmaceutical space and its specific contributions to the ATMP Sandbox remain to be seen as these initiatives progress. Readers should note that this information is based on industry recognition and does not constitute an endorsement of specific medical services or treatments.